|
Published by: BCC Research
Published: Jun. 1, 2004 - 142 Pages
Table of Contents
Introduction
Study Goals And Objectives
Scope Of Study
Methodology And Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Disclaimer
Executive Summary
Summary Table:
Worldwide Market Size Of Blood Disorder Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Summary Figure:
Worldwide Market Size Of Blood Disorder Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Industry Overview
Structure And Function Of The Hematological System
Bone Marrow
Blood Cells
Red Blood Cells
White Blood Cells
Platelets
Spleen
Lymph System
Liver
Normal Clotting Mechanisms
Effects Of Aging On The Hematologic System
Blood-Related Medical Conditions
Anemia
Table 1 Common Causes Of Anemia
Anemia Caused By Decreased Erythrocyte Production
Iron Deficiency Anemia
Thalassemia
Megaloblastic Anemia
Vitamin B12 Deficiency
Anemia Of Chronic Disease
Aplastic Anemia
Anemia Caused By Blood Loss
Anemia Caused By Increased Erythrocyte Destruction
Sickle Cell Disease
Glucose-6-Phosphate Dehydrogenase Deficiency
Acquired Hemolytic Anemia
Polycythemia
Table 2 Types Of Anemia
Hemophilia
Table 3 Common Causes Of Hemophilia
Neutropenia
Table 4 Common Infectious Causes Of Neutropenia
Table 5 Common Medication Causes Of Anemia
Thrombocytopenia
Table 6 Common Causes Of Thrombocytopenia
Thrombosis
Thromboembolus
Deep Vein Thrombosis
Table 7 Common Causes Of Thrombosis
Demographics
Table 8 Estimated U.S. Cases Of Selected Chronic Conditions/Diseases Treated With Blood Treatments, 2003
Figure 1 Estimated U.S. Cases Of Selected Leading Chronic Conditions/Diseases Treated With Blood Treatments, 2003
Table 9 Estimated Worldwide Cases Of Selected Chronic Conditions/Diseases Treated With Blood Treatments, 2003
Figure 2 Estimated Worldwide Cases Of Selected Leading Chronic Conditions/Diseases Treated With Blood Treatments, 2003
Table 10 U.S. Population By Selected Age Groups And By Percent Of Total Population, Through 2008 (Millions)
Figure 3 U.S. Population By Selected Age Groups, 2002-2008 (Millions)
Table 11 Worldwide Population By Selected Age Groups And By Percent Of Total Population, Through 2008 (Millions)
Figure 4 Worldwide Population By Selected Age Groups, 2002, 2003 And 2008 (Millions)
Licensing Disputes
Amgen And Ortho Biotech
Epogen
Procrit
Amgen And Transkaryotic Technologies
Education/Resources
Telemedicine For Hemophilia
Education
Reimbursement Issues
Cost
Pharmaceutical Landscape Changes
Impact Of Biotechnology
Table 12 Marketed Biotechnology Blood Treatments
Table 13 Marketed Biotechnology Product Impact
Biotechnology Products On The Market For Blood Disorders
Recombinant Human Erythropoietin
Leukine
Neupogen
Reopro
Retavase
Activase
Integrilin
Angiomax
Tnkase
Computers, Lifestyle, And Dvt
Medicare And The Elderly
Airline Travel Issues
Solutions To Airline-Caused Dvt
Pharmaceutical Rebate Issues
Rebate System Complexity
Product Segments By Type
Anemia Treatments
Anabolic Steroids
Cyanocobalamin And Combinations
Erythropoiesis Stimulants
Folic Acid And Derivatives
Iron And Derivatives
Hemophilia Treatments
Antihemophilic Factor
Anti-Inhibitor Coagulant Complex
Factor Ix Complex
Neutropenia Treatments
Granulocyte Colony Stimulating Factor
Granulocyte Macrophage Colony Stimulating Factor
Thrombosis Treatments
Anticoagulants
Antiplatelet Agents
Antithrombin Iii Agents
Thrombin Inhibitors
Thrombolytic Agents
Market Size And Growth
Table 14 Worldwide Market Size Of Blood Disorder Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 5 Worldwide Market Size Of Blood Disorder Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Blood Disorder Treatment Market By Geography
Table 15 Geographical Distribution Of Revenues In The Worldwide Blood Disorder Treatments Market At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 6 Geographical Distribution Of Revenues In The Worldwide Blood Disorder Treatments Market At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Blood Disorder Treatment Markets By Segment
Anemia Treatments Market
Table 16 Worldwide Market Size Of Anemia Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 7 Worldwide Market Size Of Anemia Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Table 17 Geographical Distribution Of Revenues In The Worldwide Anemia Treatments Market At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 8 Geographical Distribution Of Revenues In The Worldwide Anemia Treatments Market At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Hemophilia Treatments Market
Table 18 Worldwide Market Size Of Hemophilia Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 9 Worldwide Market Size Of Hemophilia Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Table 19 Geographical Distribution Of Revenues In The Worldwide Hemophilia Treatments Market At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 10 Geographical Distribution Of Revenues In The Worldwide Hemophilia Treatments Market At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Neutropenia Treatments Market
Table 20 Worldwide Market Size Of Neutropenia Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 11 Worldwide Market Size Of Neutropenia Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Table 21 Geographical Distribution Of Revenues In The Worldwide Neutropenia Treatments Market At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 12 Geographical Distribution Of Revenues In The Worldwide Neutropenia Treatments Market At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Thrombosis Treatments
Table 22 Worldwide Market Size Of Thrombosis Treatments By Revenues At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 13 Worldwide Market Size Of Thrombosis Treatments By Revenues At Manufacturers' Sales Levels, 2001-2008 ($ Millions)
Table 23 Geographical Distribution Of Revenues In The Worldwide Thrombosis Treatments Market At Manufacturers' Sales Levels, Through 2008 ($ Millions)
Figure 14 Geographical Distribution Of Revenues In The Worldwide Thrombosis Treatments Market At Manufacturers' Sales Levels, 2001-2003 And 2008 ($ Millions)
Research And Development
Table 24 Selected Blood Disorder Treatments In Development
Treatments Awaiting Approval/Phase Trials
Awaiting Approval
Advate
Angiomax
Hemopure
Phase Iii Clinical Trials
Dynepo
Flocor
Eculizumab
Exanta
Idraparinux
Polyheme
Procrit
Refacto Af
Rituxan
Phase Ii Clinical Trials
#
Amd3100
Azd6140
Cera
Decitabine
Hemolink
Hemoxin
Ica-17043
Marstem
R744
Razaxaban
Rnapc2
Phase I Clinical Trials
#
40sd02
Azd9684
Bay 59-7939
Coagulin-B
Dx-88
Factor Viii Gene Therapy
Gh9001
Iron Chelator
Toleragen
Pld-117
Pt-100
R1516
Sr 123781
Atryn
Industry Structure
Competitive Analysis
Table 25 Total Worldwide Manufacturers' Market Shares Of Blood Disorder Treatments By Revenues At Manufacturers' Sales Levels, 2003
Figure 15 Total Worldwide Manufacturers' Market Shares Of Blood Disorder Treatments, By Revenues, At Manufacturers' Sales Levels, 2003
Industry Participants By Product Type
Table 26 Blood Disorder Treatment Manufacturers By Product Type, 2003
Patents
Patent Analysis By Manufacturer
Table 27 Selected Manufacturer Patents For Blood Disorder And Related Technology By Application, 1976-Present
Patents By Application
Anemia Applications
Hemophilia
Neutropenia
Thrombosis
Leading Market Manufacturers
Table 28 Patent Analysis By Selected Leading Blood Disorder Treatment Manufacturers, 1976-Present
Company Profiles
Abbott Laboratories
History
Amgen, Inc.
History
Astrazeneca, Plc
History
Aventis Behring
History
Baxter Intl., Inc.
History
Bayer Ag
History
Biopure Corp.
History
Bristol-Myers Squibb Co.
History
Boehringer Ingelheim, Gmbh
History
Chugai Pharmaceutical Co., Ltd.
History
Eli Lilly & Company
History
Genentech, Inc.
History
Glaxosmithkline, Plc
History
Millennium Pharmaceuticals, Inc.
History
Novo Nordisk A/S
History
Ortho Biotech Products, Lp
History
Otsuka America, Inc.
History
Pfizer, Inc.
History
Roche
History
Sankyo Co., Ltd.
History
Sanofi-Synthelabo
History
Schering-Plough Corp.
History
Shire Pharmaceuticals Group, Plc
History
Wyeth
History
Appendices
Company Contact Information
Table 29 Extended Company List
Blood Disorder Associations And Resources Contact Information
AbstractThis timely BCC report details the market for blood disorder treatments. Several key issues are discussed in detail including the great need to educate patients and others about blood clots. The impact of thrombosis is underestimated. More than five million individuals are affected each year and it is the third most common cardiovascular event worldwide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) account for more than 250,000 hospitalizations in the United States each year. DVT and PE can be silent killers, because patients do not always present with typical signs and symptoms. That makes the detection of DVT and PE much more difficult. Education seems to be the key to addressing this need. The report contains: Identification of the different products used to treat various blood disorders; Details on the blood disorder market size and its participants; Discussion of products in research and development; Details of the industry, its relationship to the health-care industry, its economic consequences and its participants; Market forecasts through 2008 for the following product segments: anemia, hemophilia, neutropenia and thrombosis.
Get Full Details About This Report >>
|
